The company’s third-quarter earnings report for fiscal 2024 showed strong sales growth and adjusted per-share earnings of ...

With Watchman, Boston Scientific estimates a 20% compound annual growth rate (CAGR) in 2025 with a high market share. Mahoney ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/98.FiJKC4GV.js ...

RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Nevro Corp (NVRO – Research Report) on January 13 and set a price target of ...

We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we ...

Axonics is known for its innovative solutions in the field of sacral neuromodulation for bladder and bowel control. This acquisition allows Boston Scientific to expand its presence in the fast ...

New technologies for atrial fibrillation, hypertension, diabetes and neurological conditions are poised for fast growth, Martha said Monday at the J.P. Morgan Healthcare Conference.

Truist Financial analyst Richard Newitter maintained a Hold rating on Nevro Corp (NVRO – Research Report) today. The company’s shares closed ...

Boston Scientific BSX is gaining from new product launches and accretive acquisitions. Yet, unfavorable currency movement and ...

In 2024, we saw another proactive year for some of the biggest names in medtech as they looked to bolster their ranks through ...